Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Heat-Killed and Live Enterococcus faecalis Attenuates Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia

  • Choi, Young-Jin (Department of Food Science and Nutrition, Dong-A University) ;
  • Fan, Meiqi (Division of Food Bioscience, College of Biomedical and Health Sciences, Konkuk University) ;
  • Tang, Yujiao (School of Bio-Science and Food Engineering, Changchun University of Science and Technology) ;
  • Iwasa, Masahiro (R&D Center, Korea BeRM Co., Ltd.) ;
  • Han, Kwon-Il (R&D Center, Korea BeRM Co., Ltd.) ;
  • Lee, Hongchan (Wiebien Hospital) ;
  • Hwang, Ji-Young (Department of Food Science and Technology, Dong-Eui University) ;
  • Lee, Bokyung (Department of Food Science and Nutrition, Dong-A University) ;
  • Kim, Eun-Kyung (Department of Food Science and Nutrition, Dong-A University)
  • Received : 2021.02.23
  • Accepted : 2021.06.08
  • Published : 2021.08.28
Download PDF
⟨ Previous Next ⟩

Abstract

In the present study, we investigated the inhibitory effect of heat-killed Enterococcus faecalis (E. faecalis) and live E. faecalis on benign prostatic hyperplasia (BPH). The BPH rat model was established by administering male rats with testosterone propionate (TP, 5 mg/kg, in corn oil) via subcutaneous injections daily for four weeks after castration. The rats were divided into five groups: Con, corn oil-injected (s.c.) + DW administration; BPH, TP (5 mg/kg, s.c.) + DW administration; BPH+K_EF, TP (5 mg/kg, s.c.) + heat-killed E. faecalis (7.5 × 1012 CFU/g, 2.21 mg/kg) administration; BPH+L_EF, TP (5 mg/kg, s.c.) + live E. faecalis (1 × 1011 CFU/g, 166 mg/kg) administration; BPH+Fi, TP (5 mg/kg, s.c.) + finasteride (1 mg/kg) administration. In both of BPH+K_EF and BPH+L_EF groups, the prostate weight decreased and histological changes due to TP treatment recovered to the level of the Con group. Both of these groups also showed regulation of androgen-signaling factors, growth factors, and apoptosis-related factors in prostate tissue. E. faecalis exhibited an inhibitory effect on benign prostatic hyperplasia, and even heat-killed E. faecalis showed similar efficacy on the live cells in the BPH rat model. As the first investigation into the effect of heat-killed and live E. faecalis on BPH, our study suggests that heat-killed E. faecalis might be a food additive candidate for use in various foods, regardless of heat processing.

Keywords

Acknowledgement

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF- 2020R1A2C1014798 and BB21+Project in 2021.

References

  1. Roehrborn CG. 2005. Benign prostatic hyperplasia: an overview. Rev. Urol. 7: S3.
  2. Coffey DS, Walsh PC. 1990. Clinical and experimental studies of benign prostatic hyperplasia. Urol. Clin. North Am. 17: 461-475. https://doi.org/10.1016/S0094-0143(21)00960-5
  3. Farnsworth WE. 1999. Estrogen in the etiopathogenesis of BPH. Prostate 41: 263-274. https://doi.org/10.1002/(SICI)1097-0045(19991201)41:4<263::AID-PROS7>3.0.CO;2-0
  4. Aryal M, Pandeya A, Bas BK, Lamsal M, Majhi S, Pandit R, et al. 2007. Oxidative stress in patients with benign prostate hyperplasia. JNMA J. Nepal Med. Assoc. 46: 103-106.
  5. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkay S, Memis A. 2007. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 51: 199-206. https://doi.org/10.1016/j.eururo.2006.05.040
  6. Awodele O, Adeyomoye AA, Awodele DF, Fayankinnu VB, Dolapo DC. 2011. Cancer distribution pattern in south-western Nigeria. Tanzan. J. Health Res. 13: 125-131.
  7. McVARY KT, Rademaker A, Lloyd GL, Gann P. 2005. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 174: 1327-1333. https://doi.org/10.1097/01.ju.0000173072.73702.64
  8. Isaacs JT, Coffey DS. 1989. Etiology and disease process of benign prostatic hyperplasia. Prostate 15: 33-50. https://doi.org/10.1002/pros.2990150506
  9. Geller J, Albert J, Lopez D, Geller S, Niwayama G. 1976. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate. J. Clin. Endocrinol. Metab. 43: 686-688. https://doi.org/10.1210/jcem-43-3-686
  10. Ho CK, Habib FK. 2011. Estrogen and androgen signaling in the pathogenesis of BPH. Nat. Rev. Urol. 8: 29-41. https://doi.org/10.1038/nrurol.2010.207
  11. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. 2013 Correlation between benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. 23: 5-10. https://doi.org/10.1097/MOU.0b013e32835abd4a
  12. Wermuth PJ, Del Galdo F, Jimenez SA. 2009. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum. 60: 1508-1518. https://doi.org/10.1002/art.24471
  13. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, Lefkowitz RJ. 2001. Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J. Biol. Chem. 276: 23155-23160. https://doi.org/10.1074/jbc.M101303200
  14. Kerry RG, Patra JK, Gouda S, Park Y, Shin HS, Das G. 2018. Benefaction of probiotics for human health: a review. J. Food Drug Anal. 26: 927-939. https://doi.org/10.1016/j.jfda.2018.01.002
  15. Wagner R, Pierson C, Warner T, Dohnalek M, Hilty M, Balish E. 2000. Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J. Food Prot. 63: 638-644. https://doi.org/10.4315/0362-028X-63.5.638
  16. Kang BS, Seo JG, Lee GS, Kim JH, Kim SY, Han YW, et al. 2009. Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J. Microbiol. 47: 101-109. https://doi.org/10.1007/s12275-008-0179-y
  17. Choi EJ, Iwasa M, Han KI, Kim WJ, Tang Y, Hwang YJ, et al. 2016. Heat-killed Enterococcus faecalis EF-2001 ameliorates atopic dermatitis in a murine model. Nutrients 8: 146. https://doi.org/10.3390/nu8030146
  18. Choi EJ, Iwasa M, Han KI, Kim WJ, Tang Y, Han WC, et al. 2016. Effect of Enterococcus faecalis EF-2001 on experimentally induced atopic eczema in mice. Food Sci. Biotechnol. 25: 1087-1093. https://doi.org/10.1007/s10068-016-0175-7
  19. Chang SJ, Lee MH, Kim WJ, Chae Y, Iwasa M, Han KI, et al. 2019. Effect of heat-killed Enterococcus faecalis, EF-2001 on C2C12 myoblast damage induced by oxidative stress and muscle volume decreased by sciatic denervation in C57BL/6 mice. J. Life Sci. 29: 215-222. https://doi.org/10.5352/JLS.2019.29.2.215
  20. Choi EJ, Lee HJ, Kim WJ, Han KI, Iwasa M, Kobayashi K, et al. 2019. Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model. PLoS One 14: e0210854. https://doi.org/10.1371/journal.pone.0210854
  21. Gu YH, Choi H, Yamashita T, Kang KM, Iwasa M, Lee MJ, et al. 2017. Pharmaceutical production of anti-tumor and immunepotentiating Enterococcus faecalis-2001 β-glucans: enhanced activity of macrophage and lymphocytes in tumor-implanted mice. Curr. Pharm. Biotechnol. 18: 653-661.
  22. Choi YJ, Fan M, Tang Y, Yang HP, Hwang JY, Kim EK. 2019. In vivo effects of polymerized anthocyanin from grape skin on benign prostatic hyperplasia. Nutrients 11: 444. https://doi.org/10.3390/nu11020444
  23. Ohtake A, Ukai M, Saitoh C, Sonoda R, Noguchi Y, Okutsu H, et al. 2006. Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure. Eur. J. Pharmacol. 545: 185-191. https://doi.org/10.1016/j.ejphar.2006.06.054
  24. Sheth SG, Flamm SL, Gordon FD, Chopra S. 1998. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 93: 44-48. https://doi.org/10.1111/j.1572-0241.1998.044_c.x
  25. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. 2006. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int. J. Oncol. 29: 305-314.
  26. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773: 1263-1284. https://doi.org/10.1016/j.bbamcr.2006.10.001
  27. Dietrich DR. 1993. Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit. Rev. Toxicol. 23: 77-109. https://doi.org/10.3109/10408449309104075
  28. Tashiro E, Tsuchiya A, Imoto M. 2007. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 98: 629-635. https://doi.org/10.1111/j.1349-7006.2007.00449.x
  29. Vela-Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C. 2005. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J. Urol. 173: 507-510. https://doi.org/10.1097/01.ju.0000150533.94952.25
  30. Dmochowski RR. 2005. Bladder outlet obstruction: etiology and evaluation. Rev. Urol. 7: S3.
  31. Boyle P, Roehrborn C, Harkaway R, Logie J, de La Rosette J, Emberton M. 2004. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur. Urol. 45: 620-627. https://doi.org/10.1016/j.eururo.2003.09.012
  32. Nickel JC. 2008. Inflammation and benign prostatic hyperplasia. Urol. Clin. North Am. 35: 109-115. https://doi.org/10.1016/j.ucl.2007.09.012
  33. Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, et al. 2008. Prostate growth and inflammation. J. Steroid Biochem. Mol. Boil. 108: 254-260. https://doi.org/10.1016/j.jsbmb.2007.09.013
  34. Chughtai B, Lee R, Te A, Kaplan S. 2011. Role of inflammation in benign prostatic hyperplasia. Rev. Urol. 13: 147.
  35. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, et al. 2007. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur. Urol. 51: 524-533. https://doi.org/10.1016/j.eururo.2006.07.016
  36. Bechis SK, Otsetov AG, Ge R, Olumi AF. 2014. Personalized medicine for the management of benign prostatic hyperplasia. J. Urol. 192: 16-23. https://doi.org/10.1016/j.juro.2014.01.114
  37. Youn DH, Park J, Kim HL, Jung Y, Kang J, Jeong MY, et al. 2017. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase. Oncotarget 8: 9500-9512. https://doi.org/10.18632/oncotarget.13430
  38. Ellem SJ, Risbridger GP. 2009. The dual, opposing roles of estrogen in the prostate. Ann. NY Acad. Sci. 1155: 174-186. https://doi.org/10.1111/j.1749-6632.2009.04360.x
  39. Lee KL, Peehl DM. 2004. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J. Urol. 172: 1784-1791. https://doi.org/10.1097/01.ju.0000133655.71782.14
  40. Dejean LM, Martinez-Caballero S, Manon S, Kinnally KW. 2006. Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins. Biochim. Biophys. Acta 1762: 191-201. https://doi.org/10.1016/j.bbadis.2005.07.002
  41. Choi MS, Chang SJ, Chae Y, Lee MH, Kim WJ, Iwasa M, et al. 2018. Anti-inflammatory effect of heat-killed Enterococcus faecalis, EF-2001. J. Life Sci. 28: 1361-1368. https://doi.org/10.5352/JLS.2018.28.11.1361